(NASDAQ:HSGX) shares saw light trading volume with 23K shares changing hands on Tuesday. Overall, volume was down 83.05% under the stocks normal daily volume.
Short traders are more bullish recently if you consider the decrease in short interest. The stock had a fall in short interest of -21.66% between September 29, 2017 and October 13, 2017. Short interest fell 5,018 over that timeframe. The days to cover decreased to 0.0 and the percentage of shorted shares is 0.00% as of October 13.
A few notable investment firms have updated their holdings. Blackrock Inc. divested its ownership by selling 1,659 shares a decrease of 55.1% as of 06/30/2017. Blackrock Inc. currently owns 1,354 shares valued at $2,000. The total value of its holdings decreased 60.0%. As of quarter end Carl Domino Inc had disposed of 7,900 shares trimming its position 8.8%. The value in dollars decreased from $155,000 to $146,000 a change of $9,000 for the reporting period.
Sabby Management, LLC trimmed its holdings by shedding 11,027 shares a decrease of 1.0% in the quarter. Sabby Management, LLC now controls 1,084,395 shares worth $1,952,000. The value of the position overall is up by 3.0%. Ubs Group Ag downsized its stake by shedding 2,876 shares a decrease of 26.6%. Ubs Group Ag claims 7,922 shares with a value of $14,000. The total value of its holdings decreased 26.3%.
In the market the company is trading down since yesterday’s close of $2.13. Shares are trading at $2.13 just a bit higher than $2.10, the 50 day moving average and a great deal higher than the 200 day moving average of $1.85. The 50 day moving average went up $0.03 or +1.43% whereas the 200 day average was up by +15.08%.
As of the last earnings report the EPS was $-1.43 and is estimated to be $-1.09 for the current year with 22,490,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-0.24 with next year’s EPS projected to be $-0.81.
Histogenics Corporation, launched on July 14, 2006, is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Business’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The Company uses regenerative medicine platform to develop its products. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Business’s Tissue Engineering Processor (TEP). The Business’s TEP is designed to mimic the conditions found in a joint so that the implant is prepared to begin functioning like normal healthy cartilage prior to implantation. When NeoCart is implanted, a bioadhesive is used to anchor NeoCart in the cartilage injury and seal the implant to the surrounding native cartilage interface..